348 related articles for article (PubMed ID: 23385375)
21. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
[No Abstract] [Full Text] [Related]
23. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
Thomas S; Aggarwal R; Jahan T; Ryan C; Troung T; Cripps AM; Raha P; Thurn KT; Chen S; Grabowsky JA; Park J; Hwang J; Daud A; Munster PN
Ann Oncol; 2016 May; 27(5):947-52. PubMed ID: 26903311
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Kelly WK; Richon VM; O'Connor O; Curley T; MacGregor-Curtelli B; Tong W; Klang M; Schwartz L; Richardson S; Rosa E; Drobnjak M; Cordon-Cordo C; Chiao JH; Rifkind R; Marks PA; Scher H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3578-88. PubMed ID: 14506144
[TBL] [Abstract][Full Text] [Related]
27. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
Bauer S; Hilger RA; Mühlenberg T; Grabellus F; Nagarajah J; Hoiczyk M; Reichardt A; Ahrens M; Reichardt P; Grunewald S; Scheulen ME; Pustowka A; Bock E; Schuler M; Pink D
Br J Cancer; 2014 Mar; 110(5):1155-62. PubMed ID: 24434430
[TBL] [Abstract][Full Text] [Related]
30. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM
Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373
[TBL] [Abstract][Full Text] [Related]
31. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
32. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Gray JE; Haura E; Chiappori A; Tanvetyanon T; Williams CC; Pinder-Schenck M; Kish JA; Kreahling J; Lush R; Neuger A; Tetteh L; Akar A; Zhao X; Schell MJ; Bepler G; Altiok S
Clin Cancer Res; 2014 Mar; 20(6):1644-55. PubMed ID: 24429877
[TBL] [Abstract][Full Text] [Related]
33. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
[TBL] [Abstract][Full Text] [Related]
35. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
[TBL] [Abstract][Full Text] [Related]
37. Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer.
Takhar HS; Singhal N; Gowda R; Penniment M; Takhar P; Brown MP
Anticancer Drugs; 2015 Nov; 26(10):1069-77. PubMed ID: 26317683
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
de Marinis F; Atmaca A; Tiseo M; Giuffreda L; Rossi A; Gebbia V; D'Antonio C; Dal Zotto L; Al-Batran SE; Marsoni S; Wolf M
J Thorac Oncol; 2013 Aug; 8(8):1091-4. PubMed ID: 23857399
[TBL] [Abstract][Full Text] [Related]
39. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
40. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
Galli M; Salmoiraghi S; Golay J; Gozzini A; Crippa C; Pescosta N; Rambaldi A
Ann Hematol; 2010 Feb; 89(2):185-90. PubMed ID: 19633847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
